The PennZone

  • Home
  • Non-profit
  • Education
  • Construction
  • Technology
  • Entertainment
  • Business
  • Legal
  • Event

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children
The PennZone/10124083

Trending...
  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • The Prolific Writer, Producer "Hunter" Is Bringing New Music For Summer Release
  • Psychiatric Hospitals Fail to Warn Electroshock Patients of FDA-Cited Risks in Estimated $7 Billion Industry
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- In a multi-institutional study, researchers in the Developmental-Behavioral Pediatrics Research Network (DBPNet), led by Children's Hospital of Philadelphia (CHOP), have conducted the first and largest analysis to date comparing the effectiveness and side effects of stimulants like methylphenidate (Ritalin) and alpha-adrenergic agonists like guanfacine (Tenex) in preschool-age children. The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors. The retrospective study was published today in JAMA.

"This is really the first study of any size to report on the frequency of improvement and side effects of drugs like guanfacine in preschool-age children," said senior author Nathan J. Blum, MD, Chief of the Division of Developmental and Behavioral Pediatrics at CHOP. "While this study confirms that clinicians are using drugs like guanfacine in preschoolers and that those drugs may be useful in some children, the research also strongly suggests we need future research to look in a rigorous way at the use of alpha-adrenergic agonists in this age group."

More on The PennZone
  • Grace Montessori School Raises $115,000 for Student Scholarships and Enhanced Programming
  • Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss
  • K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
  • Connecta Satellite Solutions Ready to Support Emergency Communications Following the Venezuela Earthquake
  • Rare 1933 Harold Weston painting will be auctioned to benefit the Keene Valley Library

To assess the use, effectiveness, and side effects of stimulants and alpha-adrenergic agonists in preschoolers, the researchers reviewed electronic health records of 497 children seen at seven DBPNet outpatient developmental-behavioral pediatric practices between January 2013 and July 2017. Children included in the study were under the age of 6 when first treated with an alpha-adrenergic agonist or stimulant.

The researchers found that 175 children (35%) were prescribed an alpha-adrenergic agonist like guanfacine, while 322 children (65%) were prescribed a stimulant like methylphenidate (Ritalin). Although both groups reported improvement in symptoms, the benefit was slightly larger among those prescribed stimulants (78% vs. 66%).

However, in terms of side effects, patients taking alpha-adrenergic agonists reported fewer side effects than those taking stimulants, with lower rates of moodiness/irritability (50% vs. 29%), appetite suppression (38% vs. 7%), and difficulty sleeping (21% vs. 11%). The only side effect that was more common for those taking alpha-adrenergic agonists than those taking stimulants was daytime sleepiness (38% vs. 3%).

The researchers also found children younger than 4 years old who were prescribed a drug like guanfacine were likely to continue using the medication for longer than if they were prescribed a stimulant. In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant. For those ages 4 to 5, there was no significant difference between medications.

"Although the retrospective nature of our study means we weren't able to tell why patients stopped a given medication rather than continued with it, these data support potentially tailoring medication based on a child's age, among other personal factors that might influence medication decisions," Blum said. "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient."

More on The PennZone
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • HomeCentris Home Health Achieves 5-Star CMS Rating
  • Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
  • Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
  • Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders

Other institutions involved in the study include Boston Children's Hospital; the Perelman School of Medicine at University of Pennsylvania; University of Oklahoma Health Sciences Center; Keck School of Medicine at University of Southern California, Los Angeles; Children's Hospital Los Angeles; Children's Hospital Colorado; Medical University of South Carolina; Stanford University; and Atrium Health.

Harstad et al. "α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder," JAMA, online May 4, 2021, DOI: 10.1001/jama.2021.6118

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Camillia Travia
Children's Hospital of Philadelphia
(425) 492-5007
[email protected]

SOURCE Children's Hospital of Philadelphia

Related Links

http://www.chop.edu
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Save 10 Percent Off Summer Stays at KeysCaribbean Resorts
  • CGI Announces Pre-Order Launch for New Integrated Behavioral Health Book
  • IDI Consulting Supports Crohn's & Colitis Foundation as Silver Sponsor for Pittsburgh Take Steps Walk
  • Prince George's County Students Now Have A Rare Opportunity In TV Film Production Career-readiness
  • City of San José Could Lose Access to Millions Under New CalEnviroScreen Tool 5.0
  • This Weekend Causeway Cove Country BBQ & Music Festival Returns for Fourth Year, Celebrating America's 250th Anniversary on the Water
  • Webtronix Designs Web Agency Launches "LocalFind" to Revolutionize AI Local SEO for Local Businesses
  • Christmas Miracle Chronicles - New movie coming up this holiday season !
  • Healthi Life, Bangkok's Urban Longevity House, Honoured at Asia-Pacific Awards 2025
  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • Week 47 Final Freedom Vigil at Alligator Alcatraz: Truth Out
  • Psychiatric Hospitals Fail to Warn Electroshock Patients of FDA-Cited Risks in Estimated $7 Billion Industry
  • EasySpanishTax.com Launches Simple DIY Modelo 210 Filing Solution for Non-Resident Property Owners in Spain
  • Finland Sets Casino Gambling Risk Limits at 2% of Income, 4 Days, 2 Game Types
  • The Prolific Writer, Producer "Hunter" Is Bringing New Music For Summer Release
  • Millennial Maven Creative Foundation Assists In Bringing Juneteenth to the FIFA World Cup Fan Festival with an Authentically Dallas Lineup
  • Two Florida Family Law Firms Named Among the State's Best Divorce Practices for 2026
  • Tacoma Arts Live And Accelerating Creative Enterprise Present Ace Showace
  • George Martinez Launches Community Re-distribution Initiative With Donation to the Gamma Alpha Alpha Chapter of Omega Psi Phi Fraternity, Inc
  • SITE Technologies Releases Industry Research Report Exposing the CapEx Intelligence Gap in Commercial Real Estate

Popular on PennZone

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 242
  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 127
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Century Fasteners Corp. Hires Tony Marano as Director of Human Resources
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • From Broken to Soaring Week 40
  • Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
  • A Brave Little Hero with Four Paws
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • A Foundational Claim in Human Secrecy Goes Public

Similar on PennZone

  • Verbica Challenges Panetta to a Televised Debate on the Issues
  • K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
  • The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
  • Webtronix Designs Web Agency Launches "LocalFind" to Revolutionize AI Local SEO for Local Businesses
  • Christmas Miracle Chronicles - New movie coming up this holiday season !
  • EasySpanishTax.com Launches Simple DIY Modelo 210 Filing Solution for Non-Resident Property Owners in Spain
  • Finland Sets Casino Gambling Risk Limits at 2% of Income, 4 Days, 2 Game Types
  • Top 5 Most Reliable Used Vans in the UK in 2026
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us